Filgrastim-related acute kidney injury in a male renal transplant recipient

Anupama, Priya Haridas; Abraham, Georgi; Koshy, Priyanka; Mathew, Milly; George, Deepu

doi:10.4103/1319-2442.235196

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post-transplant neutropenia was associated with a 1.59-fold loss of graft and 1.74fold increased risk of death, but G-CSF did not increase the risk of graft loss.2 However, the use of G-CSF in transplant patients may increase the risk of rejection by overstimulating the immune system via leukocyte precursors. 30,36,37 Colquhoun et al 38 only reported 1 clinically and biopsy-documented rejection episode among 18 liver transplant recipients who received G-CSF for reversal of neutropenia. Similarly, G-CSF treatment has been reported to be associated with deterioration of graft function in a kidney recipient.…”

Section: Discussionmentioning

confidence: 99%

“…36 The results of several studies in mouse models of acute renal failure indicate contradictory effects of G-CSF on renal function, because G-CSF can attenuates or worsens renal injury in different settings. 39 Anupama et al 37 described a kidney transplant patient with biopsyproved acute tubular injury probably due to G-CSF therapy for profound leukopenia. The patient developed acute kidney injury with severe musculoskeletal pain four days after receiving G-CSF, and returned to near baseline creatinine in two weeks.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience

Sayilar¹,

Çelikçi²,

Ayar³

et al. 2020

Turkish Journal of Internal Medicine

View full text Add to dashboard Cite

Introduction. Granulocyte colony-stimulating factor (G-CSF) therapy is commonly used in kidney and liver transplant recipients with severe neutropenia. However, rapid and high increases in neutrophil counts of some patients may occur during treatment. This retrospective study aimed to determine the efficacy and safety of G-CSF treatment in neutropenic kidney transplant recipients. Methods. Eight kidney transplant recipients treated with G-CSF for drug-induced neutropenia (neutrophil count <1000 cells/µL) were included in the study. Daily renal function tests, leukocyte (WBC) and absolute neutrophil counts were measured. Results. The median duration of G-CSF treatment was 4 days (2-5). The median WBC and neutrophil counts elevated from 1130 and 565 cells/µL to 4400 and 1950 cells/µL after treatment, respectively (p=0.012). The median peak WBC and neutrophil counts during treatment were 18,045 and 16,445 cells/µL, respectively. The WBC counts returned to normal limits after a median of 22 days from the maximum value. No acute rejection was observed within three months of discontinuation of treatment. Conclusions. G-CSF may be a useful therapeutic alternative for kidney recipients with severe neutropenia. It seems reasonable to withdraw G-CSF treatment when WBC and neutrophil counts reach certain cutoff values during treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%